|
1
|
DeSantis CE, Fedewa SA, Goding Sauer A,
Kramer JL, Smith RA and Jemal A: Breast cancer statistics, 2015:
Convergence of incidence rates between black and white women. CA
Cancer J Clin. 66:31–42. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Callahan R and Hurvitz S: Human epidermal
growth factor receptor-2-positive breast cancer: Current management
of early, advanced, and recurrent disease. Curr Opin Obstet
Gynecol. 23:37–43. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sauter G, Lee J, Bartlett JMS, Slamon DJ
and Press MF: Guidelines for human epidermal growth factor receptor
2 testing: Biologic and methodologic considerations. J Clin Oncol.
27:1323–1333. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hoeferlin LA, E Chalfant C and Park MA:
Challenges in the treatment of triple negative and
HER2-overexpressing breast cancer. J Surg Sci. 1:3–7.
2013.PubMed/NCBI
|
|
6
|
Fragomeni SM, Sciallis A and Jeruss JS:
Molecular subtypes and local-regional control of breast cancer.
Surg Oncol Clin N Am. 27:95–120. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Daniel AR, Hagan CR and Lange CA:
Progesterone receptor action: Defining a role in breast cancer.
Expert Rev Endocrinol Metab. 6:359–369. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Toft DJ and Cryns VL: Minireview:
Basal-Like breast cancer: From molecular profiles to targeted
therapies. Mol Endocrinol. 25:199–211. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hanna S and El-Sibai M: Signaling networks
of Rho GTPases in cell motility. Cell Signal. 25:1955–1961. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zandvakili I, Lin Y, Morris JC and Zheng
Y: Rho GTPases: Anti- or pro-neoplastic targets? Oncogene.
36:3213–3222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Al-Koussa H, Atat OE, Jaafar L, Tashjian H
and El-Sibai M: The role of Rho GTPases in motility and invasion of
glioblastoma cells. Anal Cell Pathol (Amst).
2020:92740162020.PubMed/NCBI
|
|
12
|
Etienne-Manneville S and Hall A: Rho
GTPases in cell biology. Nature. 420:629–635. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zgheib P, Daher CF, Mroueh M, Nasrallah A,
Taleb RI and El-Sibai M: Daucus carota pentane/diethyl ether
fraction inhibits motility and reduces invasion of cancer cells.
Chemotherapy. 60:302–309. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nasrallah A, Saykali B, Al Dimassi S,
Khoury N, Hanna S and El-Sibai M: Effect of StarD13 on colorectal
cancer proliferation, motility and invasion. Oncol Rep. 31:505–515.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Perry JA and Maddox AS: Uncovering the
secret life of Rho GTPases. Elife. 8:e532762019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li L, Zhao GD, Shi Z, Qi LL, Zhou LY and
Fu ZX: The Ras/Raf/MEK/ERK signaling pathway and its role in the
occurrence and development of HCC. Oncol Lett. 12:3045–3050. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shapiro P: Ras-MAP kinase signaling
pathways and control of cell proliferation: Relevance to cancer
therapy. Crit Rev Clin Lab Sci. 39:285–330. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu S, Moayeri M and Leppla SH: Anthrax
lethal and edema toxins in anthrax pathogenesis. Trends Microbiol.
22:317–325. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bachran C and Leppla S: Tumor targeting
and drug delivery by anthrax toxin. Toxins (Basel). 8:1972016.
View Article : Google Scholar
|
|
20
|
Agrawal A and Pulendran B: Anthrax lethal
toxin: A weapon of multisystem destruction. Cell Mol Life Sci.
61:2859–2865. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Frankel AE, Koo HM, Leppla SH, Duesbery NS
and Vande Woude GF: Novel protein targeted therapy of metastatic
melanoma. Curr Pharm Des. 9:2060–2066. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kassab E, Darwish M, Timsah Z, Liu S,
Leppla SH, Frankel AE and Abi-Habib RJ: Cytotoxicity of anthrax
lethal toxin to human acute myeloid leukemia cells is nonapoptotic
and dependent on extracellular signal-regulated kinase 1/2
activity. Transl Oncol. 6:25–32. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Koo HM, VanBrocklin M, McWilliams MJ,
Leppla SH, Duesbery NS and Vande Woude GF: Apoptosis and
melanogenesis in human melanoma cells induced by anthrax lethal
factor inactivation of mitogen-activated protein kinase kinase.
Proc Natl Acad Sci USA. 99:3052–3057. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Abi-Habib RJ, Singh R, Liu S, Bugge TH,
Leppla SH and Frankel AE: A urokinase-activated recombinant anthrax
toxin is selectively cytotoxic to many human tumor cell types. Mol
Cancer Ther. 5:2556–2562. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Abi-Habib RJ, Urieto JO, Liu S, Leppla SH,
Duesbery NS and Frankel AE: BRAF status and mitogen-activated
protein/extracellular signal-regulated kinase kinase 1/2 activity
indicate sensitivity of melanoma cells to anthrax lethal toxin. Mol
Cancer Ther. 4:1303–1310. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Duesbery NS, Resau J, Webb CP, Koochekpour
S, Koo HM, Leppla SH and Vande Woude GF: Suppression of
ras-mediated transformation and inhibition of tumor growth and
angiogenesis by anthrax lethal factor, a proteolytic inhibitor of
multiple MEK pathways. Proc Natl Acad Sci USA. 98:4089–4094. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Alfano RW, Leppla SH, Liu S, Bugge TH,
Herlyn M, Smalley KS, Bromberg-White JL, Duesbery NS and Frankel
AE: Cytotoxicity of the matrix metalloproteinase-activated anthrax
lethal toxin is dependent on gelatinase expression and B-RAF status
in human melanoma cells. Mol Cancer Ther. 7:1218–1226. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Al-Dimassi S, Salloum G, Saykali B, Khoury
O, Liu S, Leppla SH, Abi-Habib R and El-Sibai M: Targeting the MAP
kinase pathway in astrocytoma cells using a recombinant anthrax
lethal toxin as a way to inhibit cell motility and invasion. Int J
Oncol. 48:1913–1920. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Khalil BD, Hanna S, Saykali BA, El-Sitt S,
Nasrallah A, Marston D, El-Sabban M, Hahn KM, Symons M and El-Sibai
M: The regulation of RhoA at focal adhesions by StarD13 is
important for astrocytoma cell motility. Exp Cell Res. 321:109–122.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Al Haddad M, El-Rif R, Hanna S, Jaafar L,
Dennaoui R, Abdellatef S, Miskolci V, Cox D, Hodgson L and El-Sibai
M: Differential regulation of rho GTPases during lung
adenocarcinoma migration and invasion reveals a novel role of the
tumor suppressor StarD13 in invadopodia regulation. Cell Commun
Signal. 18:1442020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jin X and Mu P: Targeting breast cancer
metastasis. Breast Cancer (Auckl). 9 (Suppl 1):S23–S34. 2015.
|
|
32
|
Shebaby WN, Mroueh M, Bodman-Smith K,
Mansour A, Taleb RI, Daher CF and El-Sibai M: Daucus carota
pentane-based fractions arrest the cell cycle and increase
apoptosis in MDA-MB-231 breast cancer cells. BMC Complement Altern
Med. 14:3872014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang SH, Sharrocks AD and Whitmarsh AJ:
MAP kinase signalling cascades and transcriptional regulation.
Gene. 513:1–13. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tawil M, Bekdash A, Mroueh M, Daher CF and
Abi-Habib RJ: Wild carrot oil extract is selectively cytotoxic to
human acute myeloid leukemia cells. Asian Pac J Cancer Prev.
16:761–767. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bekdash A, Darwish M, Timsah Z, Kassab E,
Ghanem H, Najjar V, Ghosn M, Nasser S, El-Hajj H, Bazerbachi A, et
al: Phospho-MEK1/2 and uPAR expression determine sensitivity of AML
blasts to a urokinase-activated anthrax lethal toxin (PrAgU2/LF).
Transl Oncol. 8:347–357. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Duesbery NS, Webb CP, Leppla SH, Gordon
VM, Klimpel KR, Copeland TD, Ahn NG, Oskarsson MK, Fukasawa K,
Paull KD and Vande Woude GF: Proteolytic inactivation of
MAP-kinase-kinase by anthrax lethal factor. Science. 280:734–737.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
During RL, Li W, Hao B, Koenig JM,
Stephens DS, Quinn CP and Southwick FS: Anthrax lethal toxin
paralyzes neutrophil actin-based motility. J Infect Dis.
192:837–845. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hernández SE, Settleman J and Koleske AJ:
Adhesion-dependent regulation of p190RhoGAP in the developing brain
by the Abl-related gene tyrosine kinase. Curr Biol. 14:691–696.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hanna S, Khalil B, Nasrallah A, Saykali
BA, Sobh R, Nasser S and El-Sibai M: StarD13 is a tumor suppressor
in breast cancer that regulates cell motility and invasion. Int J
Oncol. 44:1499–1511. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Al-Koussa H, Al-Haddad M, Abi-Habib R and
El-Sibai M: Human recombinant arginase I [HuArgI
(Co)-PEG5000]-induced arginine depletion inhibits colorectal cancer
cell migration and invasion. Int J Mol Sci. 20:60182019. View Article : Google Scholar
|
|
41
|
El-Sibai M, Pertz O, Pang H, Yip SC,
Lorenz M, Symons M, Condeelis JS, Hahn KM and Backer JM:
RhoA/ROCK-mediated switching between Cdc42- and Rac1-dependent
protrusion in MTLn3 carcinoma cells. Exp Cell Res. 314:1540–1552.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhou X and Zheng Y: Cell type-specific
signaling function of RhoA GTPase: Lessons from mouse gene
targeting. J Biol Chem. 288:36179–36188. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sadok A and Marshall CJ: Rho GTPases:
Masters of cell migration. Small GTPases. 5:e297102014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sakurai-Yageta M, Recchi C, Le Dez G,
Sibarita J-B, Daviet L, Camonis J, D'Souza-Schorey C and Chavrier
P: The interaction of IQGAP1 with the exocyst complex is required
for tumor cell invasion downstream of Cdc42 and RhoA. J Cell Biol.
181:985–998. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
National Institutes of Health (US), .
Understanding Cancer. NIH Curriculum Supplement Series [Internet].
National Institutes of Health (US). 2007, [cited 2020 Apr 10].
Available from:. simplehttps://www.ncbi.nlm.nih.gov/books/NBK20362/
|
|
46
|
Faltas B: Cornering metastases:
Therapeutic targeting of circulating tumor cells and stem cells.
Front Oncol. 2:682012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Nicolas S, Abdellatef S, Haddad MA,
Fakhoury I and El-Sibai M: Hypoxia and EGF stimulation regulate
VEGF expression in human glioblastoma multiforme (GBM) Cells by
differential regulation of the PI3K/Rho-GTPase and MAPK pathways.
Cells. 8:13972019. View Article : Google Scholar
|
